摘要
目的采用反映心血管系统不同病理生理状态的生化标志物心肌肌钙蛋白I(cTnI)、缺血修饰白蛋白(IMA)和高敏C反应蛋白(hs-CRP)进行联合检测,以确定其在冠状动脉硬化性心脏病中的应用价值和临床意义。方法应用统一的酶联免疫吸附试验(ELISA)试剂盒先检测142例冠心病患者的血清cTnI,以是否超过临界值(0.173 ng/mL)将患者分为2组[cTnI未升高(<0.173 mg/mL)组91例、cTnI升高(≥0.173 ng/mL)组51例];同时以78名健康体检者作为正常对照组,进行IMA和hs-CRP的联合检测。结果与正常对照组比较,冠心病cTnI未升高组的IMA和hs-CRP检测值稍有增高(P<0.05);而冠心病cTnI升高组的IMA和hs-CRP检测值均呈明显升高(P<0.01)。在冠心病cTnI未升高组中有27例(30%)患者出现IMA轻度升高,有34例(37%)患者出现hs-CRP升高。结论 cTnI、IMA和hs-CRP联合检测对判断心肌缺血和损伤程度有重要价值。三者之间有互补作用,联合应用可明显提高心肌缺血和损伤状况的检出。
Objective To investigate the application and clinical significance of combined determination of cardiac troponin I（cTnI） ,ischemia modified albumin（IMA） and high sensitive C reactive protein（hs-CRP） in coronary heart disease. Methods Enzyme-linked immunosorbent assay （ELISA） kits from the same company were used to measure the all markers. According to the measured results of cTnI were higher or not than the reference value （0. 173ng/mL）, 142 patients were classified into 2 groups [ cTnI non-increasing （ 〈 0. 173 ng/mL） group： 91 cases, cTnI increasing （≥0.173 ng/mL） group： 51 cases]. A total of 78 healthy subjects were enrolled as controls. The combined determination of cTnI, IMA and hs-CRP was performed. Results Among coronary heart disease patients in cTnl non- increasing group, their IMA and hs-CRP levels increased slightly compared with those in the control group （P 〈0. 05）. The IMA and hs-CRP levels among coronary heart disease patients in cTnI increasing group increased significantly（ P 〈 0.01）. Among coronary heart disease paritents in cTnI non-increasing group, the IMA levels of 27 patients （30%） increased slightly, and the hs-CRP levels of 34 patients （37%） increased. Conclusions The combined determination of cTnI, IMA and hs-CRP has complementation significance in diagnosis of myocardial ischemia and myocardial injury.
出处
《检验医学》
CAS
2012年第5期361-363,共3页
Laboratory Medicine
关键词
心肌肌钙蛋白I
缺血修饰白蛋白
高敏C反应蛋白
冠心病
Cardiac troponin I
Ischemia modified albumin
High sensitive C reactive protein
Coronary heart disease
